InxMed Reports Positive Phase Ib/II Data for Ifebemtinib
NANJING, China, Aug 28, 2026 InxMed Co., Ltd. announced the publication in The Lancet Oncology of clinical results evaluating...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NANJING, China, Aug 28, 2026 InxMed Co., Ltd. announced the publication in The Lancet Oncology of clinical results evaluating...
INDIANAPOLIS, U.S., Aug 28, 2026 Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
SOPHIA ANTIPOLIS, FRANCE, Aug 27, 2026 Nicox SA announced that the U.S. Food and Drug Administration (FDA) has accepted...
SOLANA BEACH, Calif., August 10, 2026 Artelo Biosciences, Inc. announced that the first patient has been dosed in the...
Aliso Viejo, California, July 27, 2026 Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal...
VAUGHAN, Ontario, May 7, 2026 Bausch + Lomb announced the European launch of its advanced Bi-Blade+â„¢ dual-port vitrectomy cutter...
CAMPBELL, CALIFORNIA | January 26, 2026 — Myra Vision, a Shifamed portfolio company, announced that the first patient has...
